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Need for chemoprophylaxis for travelers to the Americas:
Yes
P. Arguin
CDC, Atlanta, GA, USA
International travelers may sometimes acquire infectious
diseases such as malaria during their journeys. This session
will be a debate about the usefulness of malaria chemopro-
phylaxis for travel to the Americas. Malaria can be a fatal
disease even when it is diagnosed early and treated cor-
rectly. It is preferable for persons at risk of infection with
malaria to prevent the infection.
doi:10.1016/j.ijid.2010.02.1536
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Need for Continuous Prophylaxis for Travelers to the
Americas: No
M. Boulos
University of Sao Paulo, Sao Paulo, Brazil
The risk a traveler becomes infected by malaria will
depend on the overall rate of malaria transmission in the
area to be visited and the extension of the traveler’s contact
with infected mosquitoes.
Topics like: 1. Wearing long-sleeve shirts and long
trousers; 2. Applying insect repellent; 3. Spraying
aerosolized insecticides in living and sleeping places;
4. Sleeping in a screened or airconditioned rooms; 5.
Sleeping on netted bed; and 6. Use mosquito coils con-
taining pyrethroids are consensual measures in all malaria
transmission areas, and the use of chemoprophylaxis are
not consensual in low endemic areas (Wyler, NEJM 1993)
My aim is convincing you that the routinely use of malaria
chemoprophylaxis is not needed in America.
The use of anti-malarial chemoprophylaxis should be
carefully directed at high risk travelers when the beneﬁt
of using anti-malarial drug regimens outweighs the risk of
adverse events. The risk for adverse events during the anti-
malarial drugs for prophylaxis is in the range of 30-40%.
Everyone knows that malaria is a disease of low incidence
in America and most of these cases are in topic areas where
tourists only occasionally reach.
A retrospective study conducted on Italian travelers
found that malaria incidence was 1.5/1000 for trips to
Africa, 0.11/1000 for trips to Asia, and 0.04/1000 for trips to
Central and South Americas. Another study among Swedish
travelers found a number four times lesser among travelers
to America (Croft AM. BMJ 2007).
The use of chemoprophylaxis against malaria in this sce-
nario, where contra-indications overlap the beneﬁts, show
us the inadequacy of routinely use of drugs to prevent
malaria in Americas. In a restrict number of cases when the
travelers must stay in remote malaria transmitting areas in
America, for long period o time, we recommend standby
treatment.
doi:10.1016/j.ijid.2010.02.1537
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hoice of Drugs for the Prophylaxis of Malaria in the Amer-
cas
. Magill
Walter Reed Army Institute of Research, Silver Spring, MD,
SA
Preparing a traveler for a trip to the Americas often
ncludes a discussion about the prevention of malaria with
ersonal protection measures to minimize mosquito bites
nd the recommendation to use a drug for chemoprophy-
axis when appropriate. The characteristics of malaria in
he Americas that differ from many other areas of the world
nclude the relatively low transmission rates, the predomi-
ance of vivax malaria in most locations, and the relatively
ide availability of quality medical care for tourists. Use
f all current approved malaria chemoprophylaxis drugs will
e discussed with special emphasis on primaquine, the only
urrently available drug that can prevent vivax malaria.
oi:10.1016/j.ijid.2010.02.1538
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scherichia coli
.-I. Morosini
Ramón y Cajal University Hospital, Madrid, Spain
Escherichia coli is a remarkably versatile organism able
o easily acquire antimicrobial resistance as well as viru-
ence determinants. E. coli is the leading pathogen causing
rinary tract infections and one of the most common organ-
sms implicated in bloodstream infections. Its ubiquity in
he community and hospital setting, together with antibi-
tic overuse, have delineated a scenario in which multidrug
esistant isolates are not infrequent and appear as a fore-
ost challenge for clinicians to achieve therapeutic success.
Beta-lactam resistance owing to the presence of
xtended-spectrum-beta-lactamases (ESBLs) is globally
pread among E. coli, particularly due to CTX-M-type
nzymes, and coexistence of more than one beta-lactamase
n the same isolate has also been observed. Moreover,
o-resistance to non-beta-lactam antimicrobials is a com-
on feature among ESBL-producers as resistance genes
o unrelated antimicrobial compounds such as aminogly-
osides, tetracyclines, sulfonamides, trimethoprim, and
hloramphenicol are simultaneously harboured by conjuga-
ive plasmids carrying transposons and/or integrons where
hese genes are located. The prevalence of certain phy-
ogroups exhibiting these multiresistant phenotypes has
ecently been associated with a genetic island that com-
rises genes encoding antibiotic resistance and virulence
n particular E. coli clones such as the ST131 clone. Con-
omitant resistance to ﬂuoroquinolones due to mutated
opoisomerases in many of these isolates is an alarming real-
ty.
Incidence of E. coli isolates carrying plasmid-AmpC
ephalosporinases is raising in many countries and, although
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antimicrobial agents, occasionally including resistance to
colistin, hence, it can be considered the paradigm of noso-
comial multiresistant bacteria.24 14
arbapenems are still broadly active against E. coli, the inci-
ence of carbapenemases merits strict supervision mainly
n geographic areas where this resistance appears to be
ndemic in other species such as Klebsiella pneumoniae.
Other resistance traits have been described in E. coli
linical isolates as plasmid-mediated quinolone resistance
ue to qnr and aac(6’)-Ib-cr genes, and the efﬂux pump
epA. Moreover, production of plasmid 16S rRNA methy-
ases has recently drawn attention as a novel aminoglycoside
esistance mechanism in pathogenic gram-negative bacte-
ia including E. coli. It confers high-level resistance to all
minoglycosides that are currently available.
Multiresistance in E. coli affects almost all antimicrobial
amilies, it is easily transmitted through successful and vir-
lent clones and can be spread from and among not only
umans but animals and food. The role of continuous antimi-
robial pressure in this phenomenon is unquestionable and
equires control measures to curtail the spread and main-
enance of these multiresistant isolates with high likelihood
f causing serious and almost untreatable infections.
oi:10.1016/j.ijid.2010.02.1539
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ultidrug resistance in Klebsiella pneumoniae
. Nordmann
Paris, France
Hospital-acquired and clinically-important Gram-
egative pathogens remain mostly Enterobacteriaceae,
seudomonas aeruginosa and Acinetobacter baumannii.
mong those Gram negatives, Klebsiella pneumoniae
emains an important source of hospital spread of multidrug
esistance. Wide-spectrum !-lactamases are increasingly
eported in Enterobacteriaceae being either clavulanic-
cid inhibited extended-spectrum !-lactamases (ESBLs) or
arbapenem-hydrolyzing !-lactamases (CHBLs). Although
rst reported in Klebsiella pneumoniae mostly from
980’s to 2000’s, ESBLs are developing rapidly among
ommunityacquired Escherichia coli. These novel ESBLs of
he CTX-M-type are reported worldwide with important
tructural and genetic diversity. Those ESBL genes may be
ransmitted from E. coli to K. pneumoniae providing a novel
ource of hospital-acquired multidrug-resistant K. pneumo-
iae since there are associated to other plasmid-mediated
esistance determinants. The CHBLs identiﬁed in Enter-
bacteriaceae are mostly metallo-!-lactamases (Ambler
lass B enzymes) of the VIM/IMP-types in hospital-acquired
. pneumoniae. The Ambler class A carbapenemases of
he KPC-type are also identifed mostly in K. pneumo-
iae, ﬁrst from the USA and then worldwide. The latest
eported CHBL in K. pneumoniae is OXA-48 mostly from
editerranean countries. All this carbapenemase producers
re difﬁcult to detect in a clinical laboratory and may
he source of multidrug resistance leading to therapeutic
eadend. K. pneumoniae will remain the most important
nterobacterial species as a source of multidrug resistance
n hospital-acquired Gram negative isolates.
oi:10.1016/j.ijid.2010.02.1540
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seudomonas aeruginosa
. Cornaglia
University of Verona, Siena, Italy
NO ABSTRACT RECEIVED
oi:10.1016/j.ijid.2010.02.1541
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volution of antimicrobial resistance in Acinetobacter
aumannii: Factors affecting multiresistance
. Vila
Hospital Clinic, School of Medicine, University of Barcelona,
arcelona, Spain
Acinetobacter baumannii are an important cause of noso-
omial infections mainly in patients in the intensive care
nits. In this presentation I will analyse the evolution of
ntimicrobial resistance, the molecular bases associated
ith the increase in antimicrobial resistance, the factors
ffecting multiresistance and the current treatment of
cinetobacter infections.
Antimicrobial resistance has steadily increased in the last
ecade. Nowadays A. baumannii clinical isolates resistant to
ll antimicrobial agents even to colistin (panresistant) have
een isolated in the nosocomial setting. Three major factors
avour the acquisition of multiresistance: 1. Intrinsic resis-
ance, mainly related to the interplay between decreased
ermeability (small number of porins) and constitutive
xpression of efﬂux pump(s) (AdeIJK, CraA); 2. Persistence
n the environment, in this sense, bioﬁlm-producing A. bau-
annii clinical isolates survive in inanimate surfaces longer
han those non-producing bioﬁlm. 3. Acquisition of genetic
lements. It has recently been shown that resistance islands
ith a variable composition of resistance determinants
nterspersed with transposons, integrons and other genetic
lements play an important role in the acquisition of mul-
iresistance. However, this is not an universal contributor
o multiresistance since target mutations, overexpression of
fﬂux pumps, and IS elements located upstream from some
esistance genes have also been found to be implicated in
ultiresistance. Although some clinical isolates are still sus-
eptible to carbapenems and colistin, and therefore these
ntimicrobial agents can continue to be used, few options
re available to treat infections caused by this microorgan-
sm. Tygecycline has been used to treat infections caused
y A. baumannii. However, emergence of resistance to this
ntimicrobial agent has been reported during treatment
hen this monotherapy.
This microorganism, albeit with slight differences
epending on the country, presents resistance to multipleoi:10.1016/j.ijid.2010.02.1542
